O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham | Strategic Alliance Partners

March 22, 2023

A review of systemic treatment options used in polycythemia vera and the roles these play in the current treatment landscape.

March 22, 2023

A brief overview of myeloproliferative neoplasms and the associated signs and symptoms commonly presenting in patients.

March 20, 2023

Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.

December 06, 2022

Rodney Rocconi, MD, discusses the impact of the phase 3 SORAYA trial in folate receptor alpha–positive ovarian cancer.

October 26, 2022

Rodney Rocconi, MD, discusses the continued exploration of antibody-drug conjugates in patients with ovarian cancer, biomarkers and agents under investigation in the space, and the ongoing research being conducted at the O'Neal Comprehensive Cancer Center.

August 04, 2022

The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham has been awarded a five-year Cancer Center Core Support Grant of $27,477,570 from the National Cancer Institute.

July 27, 2022

TogetHER for Health is honoring the contributions of the University of Alabama at Birmingham’s Isabel Scarinci, PhD, with the first-ever Trailblazer Award for her tireless dedication to saving women’s lives both in Alabama and across the world.

July 26, 2022

Casey Weaver, MD, the Wyatt and Susan Haskell Endowed Chair for Medical Excellence in the Department of Pathology, was elected to the prestigious and esteemed National Academy of Sciences.

December 20, 2021

The potent, highly selective, next-generation PI3Kδ inhibitor parsaclisib demonstrated activity and an acceptable safety profile in patients with Bruton tyrosine kinase inhibitor-naïve relapsed/refractory mantle cell lymphoma.

July 02, 2021

This coalition of clinical research sites will partner with Genentech to advance the representation of diverse patient populations in the company’s oncology clinical trials.

May 14, 2021

Amitkumar Mehta, MD, the safety profile of liso-cel and how it is advancing the relapsed/refractory large B-cell lymphoma treatment paradigm.

April 14, 2021

Luciano J. Costa, MD, PhD, discusses the evolving treatment paradigm in newly diagnosed multiple myeloma.

November 12, 2020

Monica L. Baskin, PhD, discusses mitigating patient concerns during the coronavirus disease 2019 pandemic in prostate cancer.

October 23, 2020

Monica L. Baskin, PhD, discusses treatment considerations in prostate cancer.

September 22, 2020

Kelly Godby, MD, discusses novel triplet combinations and how they are leading the key developments made in the treatment of patients with relapsed/refractory multiple myeloma in recent years.

September 17, 2020

Susan Bal, MD, discusses key trials in the multiple myeloma space.

September 14, 2020

Luciano J. Costa, MD, PhD, discusses the promising role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

September 09, 2020

Luciano J. Costa, MD, PhD, discusses remaining challenges with investigational CAR T-cell therapies in relapsed/refractory multiple myeloma.

August 24, 2020

Luciano J. Costa, MD, discusses the emerging role of CAR T-cell therapy in relapsed/refractory multiple myeloma, investigational products such as ide-cel, orva-cel, and JNJ-4528, and early intervention strategies to manage the toxicities associated with these products.

August 06, 2020

Luciano J. Costa, MD, PhD, discusses unmet need​s in relapsed/refractory multiple myeloma.